Studies of the InCise™ Multileaf Collimator (MLC) for the CyberKnife M6™ System Reinforce its Accuracy, Reliability and Precise Dose Delivery

SUNNYVALE, Calif., July 14, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that studies on the clinical use of the CyberKnife® System, the only robotic SBRT system capable of tracking and automatically correcting for target motion, continue to demonstrate the benefits of its precise, innovative treatment delivery techniques. More than 30 studies were presented during poster and oral sessions at the 57th Annual Meeting of the American Association of Physicists in Medicine (AAPM) held in Anaheim, California, July 12 – July 16, 2015.

For more information on the CyberKnife System, visit http://www.accuray.com/solutions/treatment-planning/cyberknife-treatment-planning-system.
Leading academic institutions, hospitals and cancer treatment centers are adopting the MLC technology and seeing its benefits in significantly reduced treatment times for a wider range of tumor types. UPMC CancerCenter, Erasmus MC Cancer Institute and European CyberKnife Center Munich shared the first presented results on the use of the InCise™ MLC for the CyberKnife M6™ System. These results showed the device was:

"Very reliable"
"Highly accurate"
"Mechanically stable"

Studies continue to validate CyberKnife System's unparalleled tumor targeting capabilities. Highlights include:

Two dosimetric studies highlight the CyberKnife System's precision.

A study undertaken at UT Southwestern Medical Center compared the CyberKnife System and linac IMRT plans of patients with early-stage larynx cancer. Researchers found the CyberKnife System was better able to reduce the radiation dose to normal tissue in high-dose regions. Clinicians can have the confidence to deliver an ablative dose to the tumor while sparing the immediately adjacent organs at risk.

A second study showed the CyberKnife Multiplan® treatment planning system provided better dose conformity and less dose to critical organs than VMAT stereotactic plans for patients with localized prostate cancer. The data demonstrated radiation dose delivery via multiple non-coplanar beams, with the CyberKnife System leads to unrivaled precision and tissue sparing. This research was conducted at Medanta - The Medicity hospital in Gurgaon, Haryana.

"Data presented at AAPM reinforce the benefits of the CyberKnife System's non-coplanar beam delivery in ensuring maximal dose distribution precision while minimizing dose to surrounding healthy tissue and organs," said Calvin Maurer, Ph.D., vice president and chief technology officer at Accuray. "With the addition of the MLC, clinicians can administer these precise treatments to a broader range of patients significantly faster. The real-world results clinicians are achieving with the MLC are consistent with those seen in the technical evaluation site experience reported at AAPM."

More HCB News